Semih TUĞRUL, Reyhan AYAZ, Oya PEKİN, Erbil ÇAKAR

KronikTrombositopenik Purpura: Olgu Sunumu

Ama~: Kronik immun trombositopenisi olan hastanm gebelikte ve dogumda tedavi yakla§zmz Olgu: 34 ya§mda hastanm gebeliginin 6.ha.ftasmda trombositopeni fark edildi ve takipler szrasmda 14. ha.ftada trombosit sayzsz 23000/~ olarak tespit edildi. Hematoloji konsultasyonunu takiben hastaya gunlilk 48 mg oral prednisolone doguma kadar kullamlmak uzere ba§landz. Prednisolon tedavisine ragmen 39. gebelik ha.ftasmda trombosit sayzsz 30000/~ olarak bulundu ve planh sezeryanla doguma karar verildi. 39. gebelik haftasmda hastaya operasyon oncesi ve operasyon szrasmda hirer unite olmak uzere top/am 2 unite trombosit aferezi verildi. Postoperatif ve operatif surec;te annede ve bebekte herhangi bir komplikasyon geli§medi. Sonu~: Kronik iTP hem annede hem de fetusta ciddi hematolojik sekele neden olabilen ve belirgin trombositopeniye yola ac;abilen bir hastahktzr. Kronik iTP ic;in ilk ilac; kotikosteroid tedavisidir. Birc;ok ara§tlrmacz fetal intrakranial kanamadan korunmak ic;in sezeryanla dogumu onermektedirler.

Chronic idiopathic thrombocytopenic purpura: a case report

Aim: The aim of the study was to present the management of a case with chronic immune thrombocytopenic purpura (ITP) during pregnancy and the management of the delivery. Case: A 34 years old pregnant women with thrombocytopenia who was found at 6 th week of gestation. Thrombocyte count decreased to 23000/~ level at 14 week of gestation. After the hematology consultation, oral prednisolone 48mg/day was initiated and continued until the delivery. Despite the prednisolone administration, thrombocyte count was 30000/~ at 39 week of gestation, cesarean delivery was planned. Patient received lunite thrombocyte apheresis before the operation and during the operation. During caesarean section the postoperative period, no maternal and neonatal complications occured. Conclusion: ITP in both the mother and the baby can cause severe hematologic sequelae of a disease with a potential and significant thrombocytopenia. The first drug in treatment of ITP is steroids. Many researchers suggest cesarean delivery to protect fetal intracranial hemorrhage.

PDF

___

1-Cines DB,Blanchette VS: Immune thrombocytopenic purpura. N Eng J Med 346:995- 1008,2002.
2- Gasim T. J Reprod Med .. Immune thrombocytopenic purpura in pregnancy: a reappraisal of obstetric management and outcome. 2011 Mar-Apr;56(3-4):163-8.
3- Samuels P, Busse/ I B , Braitman L E, Tomasld A, Druztn ML et al. Estimation of the risk of thrombocytopenia in the offspring of pregnant women with presumed immune thrombocytopenic purpura. N Eng/ J Med 1990; 323;229-35.
4- Bockenstedt PL. Thrombocytopenia in pregnancy. Hematol Oncol ClinNorthAm. 2011 Apr;25(2):293- 310.
5- Burrows RF, Kelton JG: fetal thrombocytopenia and its relation to maternal thrombocytopenia. N Eng! J Med 329:1463.a, 1993
6- Levy JA, Murphy LD Thrombocytopenia in pregnancy . . JAm Board Fam Pract.2002 JulAug; 15(4):290-7
7- George JG, Woolf SH, Raskob GE, et a/: Idiopathic thrombocytopenic purpura : A practice guidelne developed by explicit methods for the American Society of Hematology. Blood 88:3, 1996.
8- Marti-Carvajal AJ, Pena-Marti GE, ComunianCarrasco G. Medical treatments for idiopathic thrombocytopenic purpura during pregnancy. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007722. Review ..
9- Christiaens CCMI, Nieuwenhuis HK, Von Dens Borne AEGKr, et al: Idiopathic thrombocytopenic purpura in pregnancy: A randomised trial on the effect of antenatal lowe dose corticosteroids on neonatal platelet count. Br J Obstetric Gynaecol 97:893, 1990
10- Yamada H, Kato EH, Kobashi G, Kishida T, Ebina Y, Kaneuchi M, Suzuki S, Fujimoto S..Passive immune thrombocytopenia in neonates of mothers with idiopathic thrombocytopenic purpura: incidence and risk factors. Semin Thromb Hemost. 1999;25(5):491-6.
11- Ghidini A, Sepulveda W, Lockwood CJ, Romero R: Complications of fetal blood sampling. Am J Obstet Gyneco/168:1339, 1993.